近日，普洛药业股份有限公司宣布与西安新通药物研究有限公司正式签署战略合作协议。此次合作聚焦于创新药物的研发与产业化，双方将充分发挥各自在原料药合成、制剂开发及临床研究方面的优势，共同推进多个高潜力候选药物的开发进程。普洛药业作为国内领先的CDMO（合同研发生产组织）企业，具备从中间体到原料药再到制剂的一体化服务能力；而西安新通则在肝病、中枢神经系统疾病等领域拥有丰富的创新药管线和临床转化经验。通过本次合作，双方旨在加速新药从实验室走向市场的步伐，提升中国原研药的全球竞争力。该协议不仅标志着两家企业在医药创新生态中的深度协同，也为国内生物医药产业链的整合与升级提供了新范式。未来，普洛药业将持续拓展与创新型生物技术公司的合作，强化其在全球医药研发外包服务领域的战略布局。
Recently, Polymed Pharmaceuticals Co., Ltd. announced the signing of a strategic cooperation agreement with Xi’an Synta Pharmaceutical Co., Ltd. The collaboration focuses on the joint development and industrialization of innovative drugs, leveraging each party’s strengths in active pharmaceutical ingredient (API) synthesis, formulation development, and clinical research to advance multiple high-potential drug candidates. As a leading Chinese CDMO (Contract Development and Manufacturing Organization), Polymed offers integrated capabilities spanning intermediates, APIs, and finished dosage forms. Xi’an Synta, meanwhile, brings extensive experience in innovative drug pipelines and clinical translation, particularly in liver diseases and central nervous system disorders. This partnership aims to accelerate the journey of new drugs from lab to market and enhance the global competitiveness of China-originated therapeutics. The agreement not only signifies deep synergy between the two companies within the pharmaceutical innovation ecosystem but also sets a new benchmark for integration and upgrading across China’s biopharmaceutical supply chain. Looking ahead, Polymed will continue expanding collaborations with innovative biotech firms to strengthen its strategic position in the global pharmaceutical R&D outsourcing landscape.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9574.html